Device Start-Up Financing Plan Should Match Exit Strategy, Experts Advise
This article was originally published in The Gray Sheet
Executive Summary
Device start-ups with limited prospects for completing an initial public offering and becoming a stand-alone operation should implement an organizational structure and financing strategy with an eye towards an acquisition exit, Allan May, president and CEO of Intella Interventional Systems advised.
You may also be interested in...
Drug Pricing Scrutiny Could Impact Device Stocks - Merrill Lynch Analyst
Stock valuations in the medical device sector may be adversely affected by the threat of federal scrutiny over U.S. prescription drug pricing, given the tendency of some investors to lump devices with drugs when making decisions, according to Merrill Lynch medical device analyst Daniel Lemaitre.
Drug Pricing Scrutiny Could Impact Device Stocks - Merrill Lynch Analyst
Stock valuations in the medical device sector may be adversely affected by the threat of federal scrutiny over U.S. prescription drug pricing, given the tendency of some investors to lump devices with drugs when making decisions, according to Merrill Lynch medical device analyst Daniel Lemaitre.
Reimbursement, Sales Critical For IPOs As Markets Reopen To Device Firms
"Reimbursement clarity" is essential for device firms in gaining investor confidence in the public equity market, Jeffrey Hoffman, health technology investment banker with U.S. Bancorp Piper Jaffray, emphasized at the recent Frost & Sullivan 5th Annual Medical Devices and Diagnostics Industry Conference in San Francisco.